ArticleFrontiers in oncology2026
Co-existence of fibroadenoma, intraductal carcinoma and invasive ductal carcinoma in the unilateral breast mass: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibroadenoma is the most common benign breast tumor. However, the coexistence of ductal carcinoma Case description: A 71-year-old woman presented with a palpable mass in her left breast, and she had a history of right-side breast cancer, which had been treated 16 years ago. Invasive ductal carcinoma was confirmed through core needle biopsy. She subsequently underwent left breast mastectomy with sentinel lymph node biopsy. Postoperative pathological examination revealed two fibroadenomas: the larger one coexisted with IDC and focal DCIS, and the small one coexisted with high-grade DCIS. Immunohistochemical analysis showed positive expression of estrogen receptor (ER) and progesterone receptor (PR), but negative expression of Her-2, demonstrating a Luminal B1 subtype (clinical stage IA). She had completed the adjuvant chemotherapy and currently received endocrine therapy. No recurrence was found during the follow-up examinations. Conclusion: Coexistence of fibroadenoma, DCIS and IDC in unilateral breast mass is rare, highlighting the importance of comprehensive preoperative evaluation, optimal surgical strategy and accurate histopathological examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.